Orthocell has been featured in The Australian Financial Review in an article by Health Editor Michael Smith titled “Perth’s billionaires pile into medtech Orthocell”.
In the article, Chairman, John Van Der Wielen discusses the enormous healthcare potential of Orthocell’s nerve repair technology Remplir, and the growing interest from high profile investors as the Company prepares to enter the US market.
Here’s an excerpt:
“Van Der Wielen says the 14-year-old company first caught his attention when he was running health insurer HBF because of its ability to reduce costs in the health system.
“While there are some amazing developments that are a good for humanity, if a drug or a prosthesis costs hundreds of thousands of dollars then we get into this debate around who pays for it,” he says.
“My advice to investors when looking at a biotech is: Has it been used in humans before and has it been proven? Does it have the ability to reduce health costs rather than increase them?”